Home

Phil Gutry

CIK 1653224 · CHIEF BUSINESS OFFICER · last filed 2022-04-13

Phil Gutry is a CHIEF BUSINESS OFFICER who has filed 32 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing shows the insider bought $20.1K of GRPH on Apr 13, 2022. Across all open-market trades the lifetime net is +$20.1K, making them a net buyer over the disclosed history. 31 SEC filings were submitted jointly with Cerecor Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

7

Total Filings

32

Lifetime Open-Market Net

$20.1K

Filer Profile

Reported Address
400 E. PRATT STREET
SUITE 606
BALTIMORE, MD 21202
Related Filers
Cerecor Inc. — 31 joint filings, latest 2021-12-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LENZ Therapeutics, Inc. (GRPH) Delisted CHIEF BUSINESS OFFICER 42,849 $22.26 $953.8K $20.1K 3 2022-04-13
AVTX Director — $16.12 — $0 1 2021-10-04
Avalo Therapeutics, Inc. (CERC) Delisted Director — $2.93 — $0 14 2021-07-02
Avalo Therapeutics, Inc. (CERCW) Delisted Director — — — $0 8 2018-10-01
Avalo Therapeutics, Inc. (CERCZ) Delisted Director — — — $0 2 2017-04-04
Avalo Therapeutics, Inc. (CERC.Z) Delisted Director — — — $0 3 2016-10-03
Avalo Therapeutics, Inc. (CERC.U) Delisted Director — — — $0 1 2015-11-12

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-04-13 LENZ Therapeutics, Inc. (GRPH) Delisted Buy (P) +5,000 $20.1K EDGAR
2022-02-18 LENZ Therapeutics, Inc. (GRPH) Delisted Grant (A) — $0 EDGAR
2021-10-04 AVTX Grant (A) — $0 EDGAR
2021-07-02 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
2021-07-01 LENZ Therapeutics, Inc. (GRPH) Delisted Mixed +102,915 $48.1K EDGAR
2021-06-17 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
2021-04-02 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
2021-01-05 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
2020-10-01 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
2020-07-01 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.